Dr. Hirshman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2301 Erwin Rd
Durham, NC 27705Phone+1 919-684-8111
Education & Training
Duke University School of MedicineClass of 2019
Certifications & Licensure
NC State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 6 citationsThe management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.Saad Atiq, Nathan Hirshman, Afreen Shariff, Tian Zhang
Urologic Oncology. 2023-10-01 - 3 citationsLR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions.Tzu-Hao Lee, Nathan Hirshman, Diana M Cardona, Carl L Berg, Kathryn J Fowler
Digestive Diseases and Sciences. 2022-11-01 - 29 citationsAssociation of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman
Biomarker Research. 2021-11-03
Press Mentions
- Management of Men with Metastatic Castration-Resistant Prostate Cancer Following Potent Androgen Receptor Inhibition: A Review of Novel Investigational TherapiesNovember 9th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
